Patents by Inventor Hans Lönn

Hans Lönn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
    Patent number: 8466284
    Abstract: The invention provides certain novel compounds as listed in the specification and pharmaceutically acceptable salts thereof and particular Forms thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: June 18, 2013
    Assignee: Astra Zeneca AB
    Inventors: David Chapman, Martin Lindsjö, Hans Lönn, Michael Lundkvist, Magnus Munck AF Rosenschöld, Antonios Nikitidis, Debra Ainge, John Pavey
  • 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial
    Patent number: 8114881
    Abstract: The invention provides compounds of formula wherein R1, R3, R4, R5, R14, X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: February 14, 2012
    Assignee: AstraZeneca AB
    Inventors: Peter Hansen, Marianne Ivarsson, Karolina Lawitz, Hans Lönn, Antonios Nikitidis, Asim Ray
  • 2-PYRIDONE DERIVATIVES AS NEUTROPHIL ELASTASE INHIBITORS AND THEIR USE
    Publication number: 20120035157
    Abstract: There are provided novel compounds of formula (I), wherein R1, R2, R4, G1, G2, L, Y and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of neutrophil elastase.
    Type: Application
    Filed: October 14, 2011
    Publication date: February 9, 2012
    Applicant: AstraZeneca AB
    Inventors: Marjana Andersson, Peter Hansen, Hans Lönn, Antonios Nikitidis, Petter Sjölin
  • 2-pyridone derivatives as neutrophil elastase inhibitors and their use
    Patent number: 8063073
    Abstract: There are provided novel compounds of formula (I), wherein R1, R2, R4, R5, G1, G2, L, Y and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of neutrophil elastase.
    Type: Grant
    Filed: September 15, 2004
    Date of Patent: November 22, 2011
    Assignee: AstraZeneca AB
    Inventors: Peter Hansen, Hans Lönn, Antonios Nikitidis
  • 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial
    Patent number: 7998984
    Abstract: The invention provides compounds of formula wherein R1, R3, R4, R5, R6, R14, X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
    Type: Grant
    Filed: May 7, 2007
    Date of Patent: August 16, 2011
    Assignee: AstraZeneca AB
    Inventors: Peter Hansen, Karolina Lawitz, Matti Lepistö, Hans Lönn, Asim Ray
  • MULTIMERIC HETEROCYCLIC COMPOUNDS USEFUL AS NEUTROPHIL ELASTASE INHIBITORS
    Publication number: 20110003858
    Abstract: The invention provides compounds of formula (I) and formula (IV) (M)-(L)-(M) (I) [(M)-(L4)]t-G (VI) wherein M, L, L4, G and t are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
    Type: Application
    Filed: September 3, 2007
    Publication date: January 6, 2011
    Inventors: Lena Bergström, Hans Lönn, Michael Lundkvist, Peter Sjö
  • 2-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL
    Publication number: 20090209555
    Abstract: The invention provides compounds of formula wherein R1, R3, R4, R5, R14, X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.
    Type: Application
    Filed: May 7, 2007
    Publication date: August 20, 2009
    Inventors: Peter Hansen, Marianne Ivarsson, Karolina Lawitz, Hans Lönn, Antonios Nikitidis, Asim Ray
  • Benzimidazol derivatives modulate chemokine receptors
    Patent number: 7388020
    Abstract: The invention provides compounds of general formula (I) wherein A, X, m, R1, N, R2, Z1, Z2, Q, R3, R4, R5, R6, R7, R8, t and R16 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy
    Type: Grant
    Filed: March 18, 2002
    Date of Patent: June 17, 2008
    Assignee: AstraZeneca AB
    Inventors: Tomas Eriksson, Svetlana Ivanova, Hans Lönn